What it's for (Indications)
- Gliclazide + Metformin fixed-dose combination therapy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.
- This medication is particularly suited for patients whose hyperglycemia is not adequately controlled with either gliclazide or metformin monotherapy, or who are already being treated with both gliclazide and metformin as separate tablets.
- It aims to reduce both fasting and post-prandial plasma glucose levels.
- The initiation of this combination should be considered only after a thorough assessment of the patient's existing glycemic control, comorbidities, and tolerance to individual components.
- It is crucial to emphasize that this therapy is an integral part of a comprehensive diabetes management plan that includes lifestyle modifications, medical nutritional therapy, and regular physical activity, rather than a standalone solution.
- The benefits derive from the synergistic effects of two distinct mechanisms of action targeting different pathophysiological aspects of Type 2 Diabetes, offering a comprehensive approach to blood glucose management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of the Gliclazide + Metformin combination must be individualized based on the patient’s current glycemic control, renal function, existing antidiabetic regimen, and tolerability, starting with a low dose and gradually titrating upwards to achieve optimal glycemic targets while minimizing side effects. The medication is typically administered orally, with meals, to mitigate gastrointestinal side effects associated with metformin and to synchronize gliclazide’s insulin-secretagogue effect with glucose intake. Available strengths vary, often combining different doses of gliclazide (e.g., 30 mg or 60 mg modified release) with metformin (e.g., 500 mg or 1000 mg). The initial dose should generally not exceed the daily dose of gliclazide or metformin already being taken by the patient, or a low starting dose if initiating combination therapy. Dosage adjustments should be made based on regular monitoring of glycemic parameters, such as fasting plasma glucose and HbA1c, and performed cautiously, typically at intervals of 1-2 weeks. The maximum daily dose of gliclazide in combination is generally limited to 120 mg (modified release), and for metformin, it is typically 2000 mg to 2500 mg, depending on the specific formulation and national guidelines. Renal function (eGFR) must be assessed prior to initiation and regularly thereafter, as dose modifications or discontinuation of the metformin component are necessary in cases of deteriorating renal function to prevent the accumulation of metformin and reduce the risk of lactic acidosis. Adjustments may also be needed in elderly patients or those with hepatic impairment due to increased risk of hypoglycemia with gliclazide. |
Safety & Warnings
Common Side Effects
- Patients receiving gliclazide + metformin combination therapy may experience various side effects, which range from mild and transient to severe and potentially life-threatening.
- The most common adverse effect associated with the gliclazide component is hypoglycemia, characterized by symptoms such as dizziness, headache, sweating, palpitations, hunger, and confusion.
- The risk of hypoglycemia is increased by irregular meal times, strenuous physical activity, alcohol consumption, renal or hepatic impairment, and co-administration with other glucose-lowering agents.
- For the metformin component, common side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhea, abdominal pain, dyspepsia, and a metallic taste in the mouth.
- These GI symptoms are often dose-dependent and can frequently be mitigated by starting with a low dose, titrating slowly, and taking the medication with food.
- A more serious but rare adverse effect of metformin is lactic acidosis, a medical emergency requiring immediate attention (detailed in the Black Box Warning).
- Long-term metformin use may also be associated with a decrease in vitamin B12 levels, potentially leading to megaloblastic anemia, necessitating periodic monitoring of B12 levels, especially in patients with risk factors.
- Other less common side effects include weight gain (more associated with gliclazide), skin reactions (e.
- g.
- , rash, pruritus), hepatic enzyme elevations, and hematological abnormalities (e.
- g.
- , leukopenia, thrombocytopenia) primarily associated with sulfonylureas.
- Patients should be educated on recognizing and managing these potential adverse reactions and advised to seek medical attention for any severe or persistent symptoms.
Serious Warnings
- Black Box Warning: WARNING: RISK OF LACTIC ACIDOSIS WITH METFORMIN The metformin component of this combination therapy carries a substantial risk of lactic acidosis, a rare but severe metabolic complication that can be fatal if not promptly recognized and managed. The onset of lactic acidosis is often insidious and accompanied by non-specific symptoms such as malaise, myalgia, respiratory distress, somnolence, and non-specific abdominal distress. More severe symptoms include hypothermia, hypotension, and resistant bradyarrhythmias. Laboratory findings typically include elevated blood lactate levels (>5 mmol/L), anion gap acidosis, and an increased lactate/pyruvate ratio. Risk factors for lactic acidosis include severe renal impairment (eGFR < 30 mL/min/1.73 m²), concomitant use of certain drugs (e.g., topiramate, zonisamide, NSAIDs), advanced age, dehydration, acute congestive heart failure, acute myocardial infarction, sepsis, hypoxemic states, excessive alcohol intake, hepatic impairment, and surgical procedures. The risk increases significantly with the degree of renal dysfunction. Metformin must be discontinued immediately if lactic acidosis is suspected. Prompt hemodialysis is recommended for lactic acidosis as it effectively clears lactate and metformin. Regularly assess renal function (eGFR) before initiating therapy and at least annually thereafter, with more frequent monitoring in elderly patients or those at risk of renal impairment. Temporarily discontinue this medication for patients undergoing radiological studies involving intravascular administration of iodinated contrast materials or for any surgical procedures requiring restricted food or fluid intake. Re-evaluate renal function 48 hours after the procedure and restart therapy only if renal function is stable and within acceptable limits.
- Several critical warnings and precautions must be considered when prescribing or administering gliclazide + metformin combination therapy to ensure patient safety and optimize clinical outcomes.
- **Hypoglycemia** is a significant risk, primarily driven by the gliclazide component, especially in patients with inadequate caloric intake, strenuous exercise, alcohol ingestion, renal or hepatic insufficiency, or concurrent use of other hypoglycemic agents.
- Patients must be educated on the symptoms of hypoglycemia and appropriate management strategies, including the intake of rapidly absorbed carbohydrates.
- **Lactic Acidosis**, while rare, is a severe and potentially fatal complication primarily associated with metformin accumulation, particularly in patients with impaired renal function (eGFR < 30 mL/min/1.
- 73m²), concomitant use of certain drugs, or conditions predisposing to hypoxemia or dehydration.
- Renal function must be assessed before initiating therapy and at least annually thereafter, with more frequent monitoring in vulnerable populations.
- The medication should be temporarily withheld during radiological procedures involving iodinated contrast agents or during surgical procedures.
- **Vitamin B12 Deficiency** can occur with long-term metformin use, necessitating periodic monitoring of B12 levels, especially in patients with pre-existing risk factors or symptoms of neuropathy or anemia.
- Caution is advised in **elderly patients**, who are more susceptible to both hypoglycemia and lactic acidosis, and often have reduced renal function; dosage adjustments and careful monitoring are paramount.
- In cases of **hepatic impairment**, the risk of hypoglycemia from gliclazide and lactic acidosis from metformin is increased, making the combination generally contraindicated or requiring extreme caution.
- **Alcohol consumption** should be limited or avoided due to increased risks of both hypoglycemia and lactic acidosis.
- During periods of **stress** such as fever, trauma, infection, or surgery, temporary discontinuation of oral antidiabetic agents and initiation of insulin therapy may be necessary to maintain glycemic control, as glycemic control can deteriorate rapidly.
How it Works (Mechanism of Action)
Gliclazide + Metformin combination therapy exerts its glucose-lowering effects through two distinct and complementary pharmacological mechanisms, addressing multiple pathophysiological defects in Type 2 Diabetes Mellitus. **Gliclazide**, a second-generation sulfonylurea, primarily acts by stimulating insulin release from the pancreatic beta cells. It achieves this by binding to the sulfonylurea receptor 1 (SUR1) on the beta-cell membrane, which leads to the closure of ATP-sensitive potassium channels. This closure results in depolarization of the beta-cell membrane, opening of voltage-gated calcium channels, and subsequent influx of calcium ions. The increased intracellular calcium then triggers the exocytosis of pre-formed insulin granules, thereby increasing insulin secretion, particularly in the presence of glucose. This action is dependent on residual pancreatic beta-cell function. **Metformin**, a biguanide, primarily functions by reducing hepatic glucose production. It achieves this through the activation of AMP-activated protein kinase (AMPK), which leads to decreased gluconeogenesis and glycogenolysis in the liver. Additionally, metformin improves insulin sensitivity in peripheral tissues, such as muscle and adipose tissue, by enhancing glucose uptake and utilization. It also delays intestinal glucose absorption, contributing to a reduction in post-prandial hyperglycemia. Importantly, metformin does not directly stimulate insulin secretion, and therefore, when used alone, carries a lower risk of hypoglycemia compared to sulfonylureas. The combination leverages these synergistic effects to provide more comprehensive glycemic control than either agent alone by addressing both insulin secretion and insulin resistance.
Commercial Brands (Alternatives)
No other brands found for this formula.